President and Chief Executive Officer · Mersana Therapeutics, Inc. (MRSN)

Michael Huber

A named executive officer of Mersana Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2024

$1,613,754

FY2023: $2,601,249

1st of 5 named executive officers at Mersana Therapeutics by FY2024 total.

5 named officers on file for Mersana Therapeutics, FY2024

See an example →

What this number hides

The filing gives the total. Mersana Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get Michael Huber’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Michael Huber and every company like it: Velarion Intel, free for 3 days, no card →

Michael Huber compensation by year

Mersana Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Mersana Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$194,311$632,500
Bonus$0$0
Stock awards$880,440$133,635
Option awards$1,133,300$518,044
Non-equity incentive$110,466$322,575
Pension and deferred compensation$0$0
All other$282,733$7,000
Total$2,601,249$1,613,754

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mersana Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001104659-25-040448, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mersana Therapeutics, Inc. filed document, accession 0001104659-25-040448. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

$2.6M
$1.6M
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Mersana Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Michael Huber · this pagePresident and Chief Executive Officer$1,613,754
Brian DeSchuytnerSenior Vice President, Chief Operating Officer and Chief Financial Officer$1,543,586
Mohan BalaSenior Vice President, Chief Development Officer$1,502,936
Timothy LowingerSenior Vice President, Chief Science and Technology Officer$1,400,535
Alejandra CarvajalSenior Vice President, Chief Legal Officer$1,359,885

The full Mersana Therapeutics compensation record

free company brief

This page is one person within Mersana Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mersana Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Mersana Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mersana Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order MRSN

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Michael Huber's compensation dossier